WE42245-header

Raise Standards for Preclinical Research: Antibody Validation

Antibodies are some of the most critical research reagents used in the lab. Poor specificity or application performance can significantly frustrate the ability to obtain good results, which can cause critical delays. Underperforming antibodies result in a lack of reproducibility, wasting time and money. To help ensure superior antibody results, we've expanded our specificity testing methodology. In this seminar,  we will present our two-part approach for validation of our antibody portfolio to ensure proper characterisation and consistency for antibodies in your laboratory.

Interrogation of Three-Dimensional Cell Models in Research

Traditionally, attempts to characterise aberrant cellular processes underlying cancer progression and the development of targeted therapies have relied upon two-dimensional (2D) cell models. While useful, these models do not accurately recapitulate the complex environment of cells in the body, both normal and transformed.  Increased interest in adopting three-dimensional (3D) cell models which better reflect the ‘natural’ setting has stemmed from studies demonstrating improved predictive clinical value of therapeutics that are screened in 3D  versus 2D cultures. While a wide range of routine analytical methods can be performed on 3D cultures, ranging from genomic through proteomic to cell-based, fluorescence imaging in particular has lent itself to the study of these model types.  When combined with antibody-based and functional biosensors, fluorescence microscopy is able to provide readouts of biological processes and regional differences throughout the sample, such as tumour spheroids, without disruption. This seminar will focus on the advantages and challenges of both labelling and imaging of structural and functional landscapes in 3D models relevant to solid tumour cell biology.

Insights into Signalling Pathways

Quantitative analysis of two signalling pathways using multiplex-immunoprecipitation, targeted mass spectrometry and western blotting. The lack of rigorously verified reagents and a reliance on semi-quantitative immunoassays limit the accurate quantitative analysis of signalling pathway proteins. Immunoprecipitation coupled with mass spectrometry (IP-MS) enables the enrichment of signalling pathway proteins, revealing protein-protein interactions and PTMs and can be used for the identification of low-abundant pathway targets and for the assessment of antibody specificity. Multiplex IP coupled with MS (mIP-MS) further enhances this workflow by simultaneously quantifying multiple proteins and their phosphorylation states in a specific signalling pathway. mIP-tMS assays allowed absolute quantitation of multiple total and phosphorylated targets from signalling pathways in low to sub-nanogram concentrations.

Leveraging Animal Models for Research

With the growing adoption of personalised medicine, recent advances in large scale and high throughput cellular analyses are helping streamline tools that make it easier to attain markers of disease status, examine tumour micro-environments at the single cell level and make for broad biomarker discovery and validation. Researchers today are seeking answers to questions regarding specific attributes of a tumour type, specific tumour cells and tumour micro-environment that are predictive of response in order to explore the immune system and identify pharmacodynamic biomarkers. This seminar will focus on addressing the common challenges cancer researchers face when working in animal models, and discuss recent advances and future prospects.

Raise Standards for Preclinical Research: Antibody Validation

Antibodies are some of the most critical research reagents used in the lab. Poor specificity or application performance can significantly frustrate the ability to obtain good results, which can cause critical delays. Underperforming antibodies result in a lack of reproducibility, wasting time and money. To help ensure superior antibody results, we've expanded our specificity testing methodology. In this seminar,  we will present our two-part approach for validation of our antibody portfolio to ensure proper characterisation and consistency for antibodies in your laboratory.

Interrogation of Three-Dimensional Cell Models in Research

Traditionally, attempts to characterise aberrant cellular processes underlying cancer progression and the development of targeted therapies have relied upon two-dimensional (2D) cell models. While useful, these models do not accurately recapitulate the complex environment of cells in the body, both normal and transformed.  Increased interest in adopting three-dimensional (3D) cell models which better reflect the ‘natural’ setting has stemmed from studies demonstrating improved predictive clinical value of therapeutics that are screened in 3D  versus 2D cultures. While a wide range of routine analytical methods can be performed on 3D cultures, ranging from genomic through proteomic to cell-based, fluorescence imaging in particular has lent itself to the study of these model types.  When combined with antibody-based and functional biosensors, fluorescence microscopy is able to provide readouts of biological processes and regional differences throughout the sample, such as tumour spheroids, without disruption. This seminar will focus on the advantages and challenges of both labelling and imaging of structural and functional landscapes in 3D models relevant to solid tumour cell biology.

Insights into Signalling Pathways

Quantitative analysis of two signalling pathways using multiplex-immunoprecipitation, targeted mass spectrometry and western blotting. The lack of rigorously verified reagents and a reliance on semi-quantitative immunoassays limit the accurate quantitative analysis of signalling pathway proteins. Immunoprecipitation coupled with mass spectrometry (IP-MS) enables the enrichment of signalling pathway proteins, revealing protein-protein interactions and PTMs and can be used for the identification of low-abundant pathway targets and for the assessment of antibody specificity. Multiplex IP coupled with MS (mIP-MS) further enhances this workflow by simultaneously quantifying multiple proteins and their phosphorylation states in a specific signalling pathway. mIP-tMS assays allowed absolute quantitation of multiple total and phosphorylated targets from signalling pathways in low to sub-nanogram concentrations.

Leveraging Animal Models for Research

With the growing adoption of personalised medicine, recent advances in large scale and high throughput cellular analyses are helping streamline tools that make it easier to attain markers of disease status, examine tumour micro-environments at the single cell level and make for broad biomarker discovery and validation. Researchers today are seeking answers to questions regarding specific attributes of a tumour type, specific tumour cells and tumour micro-environment that are predictive of response in order to explore the immune system and identify pharmacodynamic biomarkers. This seminar will focus on addressing the common challenges cancer researchers face when working in animal models, and discuss recent advances and future prospects.